Retinal vessel dilator and pharmaceutical composition
By using nomiglitatin as a retinal vasodilator and combining it with a pharmaceutically acceptable carrier to prepare a drug composition, the problem of the difficulty in improving retinal circulation disorders in the prior art is solved, and the effect of early treatment and prevention of retinal-related diseases is achieved.
Patent Information
- Application Number
- CN202380027300.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-15
- Filing Date
- 2023-03-10
- Publication Date
- 2024-11-22
AI Technical Summary
Existing technologies are insufficient to improve retinal circulatory disorders in the early stages, making it difficult to control the symptoms of retinal-related diseases. Furthermore, existing drug treatments are either highly invasive or costly.
Nobiglitin, as a retinal vasodilator, is combined with a pharmaceutically acceptable carrier to prepare a pharmaceutical composition for the treatment or prevention of retinal circulatory disorders.
Nobiglitin exhibits a strong retinal vasodilatory effect, can improve retinal circulatory disorders in the early stages, reduce side effects, and is suitable for the treatment and prevention of a variety of retinal-related diseases.
Smart Images

Figure BDA0005040625750000031 
Figure BDA0005040625750000151 
Figure HDA0005040625770000011
Abstract
Description
Technical Field
[0001] The invention relates to a retinal vasodilator and a pharmaceutical composition.
[0002] This application claims priority based on Japanese Patent Application No. 2022-040830 filed in Japan on March 15, 2022, and the contents are incorporated herein by reference. Background Art
[0003] Retinal circulation disorders occur earlier than the obvious manifestations of retinal-related diseases, and are one of the causes of various retinal-related diseases. When retinal circulation disorders occur, angiogenesis occurs to compensate for the lack of blood flow. The walls of the new blood vessels formed in this way are fragile and prone to bleeding or leakage of blood components. Therefore, edema occurs, causing symptoms such as decreased vision, narrow visual field, and visual field defects. When symptoms develop, laser photocoagulation or vitrectomy are used, but these treatment methods are highly invasive. For macular edema, intravitreal injections of anti-VEGF drugs are performed, but the drug price is high. In addition, intravitreal injections are invasive, so it is considered difficult to perform repeatedly.
[0004] It is believed that if retinal circulation disorders can be improved earlier before edema etc. occurs, the manifestation of symptoms of retinal diseases can be suppressed. Retinal circulation improving drugs are used to improve retinal circulation disorders, but it is difficult to achieve an effective concentration for retinal vasodilation in vivo with existing drugs.
[0005] Nobiletin is a flavonoid contained in citrus fruits such as Shikuwasa. Nobiletin has been reported to have a vasodilatory effect on rat aorta (Non-Patent Document 1) and rat mesenteric artery (Non-Patent Document 2) pre-contracted with phenylephrine. In Non-Patent Document 1, it is believed that nobiletin dilates rat aorta in an endothelium-independent manner. In Non-Patent Document 2, it is believed that nobiletin dilates rat mesenteric artery in an endothelium-dependent manner.
[0006] The mechanism of vasodilation differs depending on the tissue in which the blood vessels are located, and the vasodilation response caused by the compound also differs depending on the tissue. For example, Non-Patent Document 2 reports that nobiletin does not cause a vasodilation response in rat pulmonary arteries.
[0007] Prior art literature
[0008] Non-patent literature
[0009] Non-patent literature 1: Kaneda et al., Endothelium-independent vasodilator effects of nobiletin in rat aorta. J Pharmacol Sci. 2019 May; 140(1): 48-53.
[0010] Non-patent document 2: Yang et al., Nobiletin Relaxes Isolated Mesenteric Arteries by Activating the Endothelial Ca2+-eNOS Pathway in Rats. J Vasc Res; 2016; 53(5-6): 330-339. Summary of the invention
[0011] Technical issues to be solved
[0012] It is believed that if retinal circulatory disturbances can be improved at an early stage, the occurrence and progression of symptoms such as edema and visual impairment can be suppressed. Therefore, there is a need to develop retinal vasodilators with fewer side effects and a high vasodilator effect.
[0013] Therefore, an object of the present invention is to provide a novel retinal vasodilator and a pharmaceutical composition comprising the retinal vasodilator.
[0014] Means used to solve problems
[0015] The present invention includes the following aspects.
[0016] [1] A retinal vasodilator comprising nobiletin.
[0017] [2] A pharmaceutical composition for treating or preventing retinal circulatory disorders, comprising the retinal vasodilator described in [1] and a pharmaceutically acceptable carrier.
[0018] Effects of the Invention
[0019] According to the present invention, a novel retinal vasodilator and a pharmaceutical composition comprising the retinal vasodilator are provided. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The results of evaluating the vasodilatory effect of nobiletin on porcine retinal excised arteries are shown.
[0021] Figure 2 The results of evaluating the vasodilatory effect of nobiletin on porcine retinal excised arteries are shown. The results of the experiment performed twice with n=5 are shown.
[0022] Figure 3 The results of evaluating the vasodilatory effect of nobiletin using porcine retinal excised arteries from which the vascular endothelium had been removed (denudated) are shown.
[0023] Figure 4 The results of evaluating the vasodilator effect of nobiletin using pig retinal excised arteries treated with ODQ, a guanylate cyclase inhibitor, are shown. DETAILED DESCRIPTION
[0024] [Retinal vasodilators]
[0025] A first aspect of the present invention is a retinal vasodilator comprising nobiliptin.
[0026] Nobiletin (2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one) is a polymethoxyflavonoid having a flavonoid skeleton. Nobiletin is represented by the following chemical formula.
[0027] [Chemical formula 1]
[0028]
[0029] Nobiletin is mainly contained in citrus fruits such as lemon, ponkan, kabosu, and tachibana, and is particularly present in the peel. Nobiletin can be extracted from the peel of these citrus fruits by a known method, or a commercially available product can be used.
[0030] "Retinal blood vessels" refer to blood vessels present in the retina. Retinal blood vessels may be retinal arteries or retinal veins. The retinal vasodilator according to this embodiment acts on retinal blood vessels to dilate the retinal blood vessels. The retinal vasodilator according to this embodiment contains nobiletin, which has a strong vasodilating effect on the retina, as an active ingredient. Therefore, the retinal vasodilator according to this embodiment exerts a strong vasodilating effect on the retinal blood vessels.
[0031] The retinal vasodilator according to the present embodiment may contain any component in addition to nobiletin. The optional component is not particularly limited. As the optional component, various additives used in the manufacture of pharmaceuticals, cosmetics, foods, etc. can be used without particular limitation. As an optional component, for example, a pharmaceutically acceptable carrier can be cited. "Pharmaceutically acceptable carrier" refers to a carrier that does not inhibit the physiological activity of the active ingredient and does not show substantial toxicity to the subject to which it is administered. "Does not show substantial toxicity" means that its components do not show toxicity to the subject to which it is administered at a commonly used dose. In the retinal vasodilator according to the present embodiment, a pharmaceutically acceptable carrier is a carrier that does not inhibit the retinal vasodilator effect of nobiletin and does not show substantial toxicity to the subject to which it is administered. Pharmaceutically acceptable carriers are generally considered to be inactive ingredients. Pharmaceutically acceptable carriers may include known so-called pharmaceutically acceptable ingredients. As pharmaceutically acceptable carriers, for example, solvents, diluents, vehicles, excipients, glidants, adhesives, granulators, dispersants, suspending agents, wetting agents, lubricants, disintegrants, solubilizers, stabilizers, emulsifiers, fillers, preservatives (e.g., antioxidants), chelating agents, surfactants, thickeners, gelling agents, buffers, water, inorganic acids, organic acids, inorganic bases, organic bases, alcohols, inorganic salts, polymer additives, metal-containing compounds, polymer carboxylic acids, etc. can be cited, but are not limited thereto. Pharmaceutically acceptable carriers can be used alone or in combination of two or more.
[0032] The dosage form of the retinal vasodilator according to the present embodiment is not particularly limited and can be any dosage form. Examples of dosage forms include tablets, granules, powders, pills, liquids, emulsions, capsules, etc. Retinal vasodilators of these dosage forms can be produced by adding appropriate additives to nobiletin according to the dosage form and preparing the drug according to a prescribed method.
[0033] The retinal vasodilator according to the present embodiment may be administered by itself to a subject in need of retinal vasodilation, or may be used by mixing with a pharmaceutical, cosmetic, food, or feed.
[0034] As subjects requiring retinal vasodilation, for example, subjects with retinal circulatory disorders such as retinal vascular stenosis or retinal vascular occlusion due to various reasons, or subjects with a high risk of developing retinal circulatory disorders can be cited. The retinal vasodilator according to this embodiment can be administered to subjects who have developed retinal circulatory disorders to improve these symptoms, and can also be administered to subjects with a high risk of developing retinal circulatory disorders to prevent these symptoms. Retinal circulatory disorders may be caused by, for example, arteriosclerosis, hypertension, diabetes, heart disease, aging, etc. Therefore, as subjects with a high risk of developing retinal circulatory disorders, for example, subjects with diseases or symptoms such as arteriosclerosis, hypertension, diabetes or heart disease, and the elderly can be cited.
[0035] The applicable subjects of the retinal vasodilator according to the present embodiment are not particularly limited as long as they are animals having a retina. Examples of applicable subjects include humans and mammals other than humans. Mammals other than humans are not particularly limited, and examples thereof include primates (monkeys, chimpanzees, gorillas, etc.), rodents (mice, hamsters, rats, etc.), rabbits, dogs, cats, cows, goats, sheep, horses, etc.
[0036] [Drug composition]
[0037] A second aspect of the present invention is a pharmaceutical composition for treating or preventing retinal circulatory disorders, comprising the retinal vasodilator according to the first aspect and a pharmaceutically acceptable carrier.
[0038] The pharmaceutical composition according to this embodiment contains nobiletin as an active ingredient. Since nobiletin has a strong vasodilatory effect on retinal blood vessels, the pharmaceutical composition according to this embodiment can be used to treat or prevent retinal circulatory disorders caused by retinal vascular stenosis or retinal vascular occlusion.
[0039] "Retinal circulation" refers to the blood flow in the retina. "Retinal circulation disorder" refers to the obstruction of blood flow in the retina. Retinal circulation disorder is a disorder caused by occlusion or stenosis of retinal blood vessels. When retinal circulation disorder caused by occlusion or stenosis of retinal blood vessels occurs, the supply of oxygen and nutrients to retinal cells and optic nerves is hindered. Retinal circulation disorder is one of the causes of various retinal related diseases. As such retinal related diseases, for example, diabetic retinopathy, retinal vein occlusive disease, retinal artery occlusive disease, age-related macular degeneration, glaucoma, central serous choroidopathy, etc. can be cited, but it is not limited to these.
[0040] Diabetic retinopathy is a disease in which chronic high blood sugar caused by diabetes leads to retinal damage. When suffering from diabetes, the sugar in the blood increases, and the retinal blood vessels are obstructed by the sugar, which can easily cause stenosis or occlusion of the blood vessels. When the retinal blood vessels are obstructed, the ischemic area gradually expands, and new blood vessels are formed to compensate for the lack of blood flow. Because the walls of the new blood vessels are fragile, they are prone to bleeding and leakage of blood components, causing macular edema. When symptoms develop, vision decreases, and tractional retinal detachment and other complications occur along with proliferative changes, and sometimes blindness can occur. In diabetic retinopathy, retinal circulation disorders occur from the initial stage, and it is believed that by improving retinal circulation disorders, the progression of symptoms can be suppressed.
[0041] The pharmaceutical composition according to this mode can be administered to an object suffering from diabetic retinopathy to improve retinal circulation disorders and inhibit the development of diabetic retinopathy. In diabetic retinopathy, retinal circulation disorders occur from the initial stage, which becomes one of the reasons for the subsequent symptom development. Therefore, the pharmaceutical composition according to this mode can be particularly appropriately applied to an object in the initial stage of diabetic retinopathy. The pharmaceutical composition according to this mode can also be administered preventively to an object suffering from diabetes and not suffering from diabetic retinopathy. In diabetic patients, the onset of diabetic retinopathy can be inhibited by improving or preventing retinal circulation disorders.
[0042] Retinal vein occlusive disease is a disease in which the retinal vein is occluded. When the retinal vein is occluded, bleeding and macular edema occur. Retinal vein occlusive disease is divided into central retinal vein disease, branch retinal vein occlusive disease, etc. according to the occluded site of the vein. The pharmaceutical composition according to this embodiment can be applied to any of central retinal vein disease and branch retinal vein occlusive disease.
[0043] The pharmaceutical composition according to this method can be administered to a subject suffering from retinal vein occlusive disease to dilate the retinal vein and improve the occlusion of the retinal vein. Retinal vein occlusive disease is prone to occur when there are symptoms such as hypertension and arteriosclerosis. Therefore, the pharmaceutical composition according to this method can also be administered preventively to a subject with hypertension and / or arteriosclerosis. In these high-risk groups, the onset of retinal vein occlusive disease can be suppressed by improving or preventing retinal circulation disorders.
[0044] Retinal artery occlusion is a disease in which the retinal artery is occluded. When the retinal artery is occluded, the supply of oxygen and nutrients to the retinal cells is interrupted, and the retinal cells die. Retinal artery occlusion is divided into central retinal artery disease, retinal artery branch occlusion, etc. according to the occlusion site of the artery. The pharmaceutical composition according to this embodiment can be applied to any of central retinal artery disease and retinal artery branch occlusion.
[0045] The pharmaceutical composition according to this method can be administered to a subject suffering from retinal artery occlusive lesions to dilate the retinal arteries and improve the occlusion of the retinal arteries. Retinal artery occlusive lesions are prone to occur when they have symptoms such as hypertension and arteriosclerosis. Therefore, the pharmaceutical composition according to this method can also be administered preventively to a subject with hypertension and / or arteriosclerosis. In these high-risk groups, the onset of retinal artery occlusive lesions can be suppressed by improving or preventing retinal circulation disorders.
[0046] Age-related macular degeneration is a disease that causes macular degeneration due to changes associated with aging. Age-related macular degeneration is divided into an exudative type with choroidal neovascularization and an atrophic type with gradual atrophy of retinal tissue. It is believed that the occurrence of choroidal neovascularization or atrophy of retinal tissue is related to retinal circulation disorders. The pharmaceutical composition according to this embodiment can also be applied to any of the exudative and atrophic age-related macular degeneration.
[0047] The pharmaceutical composition according to this method can be administered to a subject suffering from age-related macular degeneration, so as to dilate retinal blood vessels, improve retinal circulation disorders and inhibit the development of age-related macular degeneration. Age-related macular degeneration is prone to occur with age, so the elderly are prone to the disease. Therefore, the pharmaceutical composition according to this method can also be administered to the elderly prophylactically. In the elderly, by improving or preventing retinal circulation disorders, the onset of age-related macular degeneration can be inhibited.
[0048] Central serous choroidopathy is a disease in which water accumulates in the macula and partial retinal detachment occurs. As a cause of water accumulation in the macula, the serous fluid in the choroid leaks to the retina due to the reduction of the barrier function of the retinal pigment epithelium. It is believed that the reduction of the barrier function of the retinal pigment epithelium is related to retinal circulation disorders. Therefore, the pharmaceutical composition according to this embodiment can be applied to central serous choroidopathy.
[0049] According to the pharmaceutical composition of this method, it is possible to administer the drug to a subject suffering from central serous retinochoroidopathy, so as to dilate the retinal blood vessels, improve retinal circulation disorders and inhibit the development of central serous retinochoroidopathy. Central serous retinochoroidopathy tends to be more common in men aged 20 to 50 years old, and is more likely to develop due to overwork, lack of sleep, stress, etc. Therefore, the pharmaceutical composition of this method can also be administered preventively to subjects with a higher risk of developing the disease as described above. In these high-risk groups, the onset of central serous retinochoroidopathy can be inhibited by improving or preventing retinal circulation disorders.
[0050] The applicable object of the pharmaceutical composition according to this embodiment is not particularly limited as long as it is an animal with a retina. For example, the applicable object can include humans or mammals other than humans. Mammals other than humans are not particularly limited, and primates (monkeys, chimpanzees, gorillas, etc.), rodents (mice, hamsters, rats, etc.), rabbits, dogs, cats, cattle, goats, sheep, horses, etc. can be mentioned.
[0051] In addition to the retinal vasodilator according to the first embodiment, the pharmaceutical composition of this embodiment further contains a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is not particularly limited, and a carrier commonly used in pharmaceuticals can be used. As specific examples of pharmaceutically acceptable carriers, the carriers listed above can be cited. The pharmaceutically acceptable carriers can be used alone or in combination of two or more.
[0052] In addition to the retinal vasodilator and the pharmaceutically acceptable carrier according to the first embodiment, the pharmaceutical composition according to the present embodiment may also contain an optional component. The optional component is not particularly limited, and general pharmaceutical additives can be used without particular restrictions. As an optional component, an active ingredient other than the retinal vasodilator according to the first embodiment may also be used. As the above-mentioned active ingredients, preservatives, antibacterial agents, vitamins and their derivatives, anti-inflammatory agents, anti-inflammatory agents, blood circulation promoters, stimulants, hormones, cooling agents, warming agents, wound healing promoters, irritation relief agents, analgesics, cell activators, plant·animal·microorganism extracts, cooling agents, enzymes, nucleic acids, anti-inflammatory analgesics, antifungal agents, antihistamines, hypnotic sedatives, sedatives, antihypertensive agents, antihypertensive diuretics, antibiotics, anesthetics, antibacterial substances, antiepileptics, coronary vasodilators, crude drugs, antipruritic agents, ultraviolet blockers, preservatives, antioxidants, etc. can be cited, but are not limited to these. As the optional components, in addition to the above, there may be mentioned, for example, flavoring agents, coloring agents, dyes, pigments, pH adjusters, metal soaps, flavoring agents, sweeteners, etc., but are not limited thereto. The optional components may be used alone or in combination of two or more.
[0053] The dosage form of the pharmaceutical composition according to the present embodiment is not particularly limited, and the dosage form commonly used as a pharmaceutical preparation can be appropriately adopted. As the dosage form of the pharmaceutical composition according to the present embodiment, for example, oral dosage forms such as tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, and emulsions, and parenteral dosage forms such as eye drops, injections, and skin external preparations can be cited. The pharmaceutical compositions of these dosage forms can be prepared according to the prescribed method.
[0054] The pharmaceutical composition according to this embodiment is preferably an oral preparation or an eye drop.
[0055] In the case of an oral preparation, as additives, for example, excipients such as glucose, lactose, D-mannitol, starch, and crystalline cellulose; disintegrants or disintegration aids such as carboxymethyl cellulose, starch, and carboxymethyl cellulose calcium; binders such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, and gelatin; lubricants such as magnesium stearate and talc; bases such as hydroxypropyl methyl cellulose, white sugar, polyethylene glycol, gelatin, kaolin, glycerin, purified water, and hard coat.
[0056] In the case of eye drops, a dispersant, a thickener, a preservative, an isotonic agent, a pH adjuster, a buffer, and the like may be used in combination as appropriate.
[0057] As the dispersant used in the eye drops, water is preferred. Water of a grade that can be used in eye drops, such as purified water, sterile purified water, water for injection, and distilled water for injection, can be used.
[0058] As the thickener used in the eye drops, for example, cellulose thickeners such as methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, etc.; vinyl thickeners such as carboxyvinyl polymer, polyvinyl alcohol (completely or partially saponified), polyvinyl pyrrolidone, etc.; sodium alginate, sodium chondroitin sulfate, polyethylene glycol, etc. can be mentioned, but it is not limited thereto. The thickener can be used alone or in combination of two or more.
[0059] Preservatives used in eye drops include, but are not limited to, inverse soaps such as benzalkonium chloride, benzethonium chloride, and chlorhexidine gluconate; parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben; and alcohols such as chlorobutanol, phenethyl alcohol, and benzyl alcohol. The preservatives may be used alone or in combination of two or more.
[0060] As isotonic agents used in eye drops, for example, sugars such as glucose, polyols such as propylene glycol, glycerol, mannitol, sorbitol, and xylitol, inorganic salts such as sodium chloride and potassium chloride, etc. can be cited, but are not limited thereto. Preservatives can be used alone or in combination of two or more.
[0061] Examples of pH adjusters used in eye drops include, but are not limited to, dilute hydrochloric acid and sodium hydroxide. The pH adjusters may be used alone or in combination of two or more.
[0062] Examples of buffers used in eye drops include, but are not limited to, sodium citrate hydrate, sodium acetate hydrate, sodium bicarbonate, tromethamine, boric acid, borax, sodium hydrogen phosphate hydrate, sodium dihydrogen phosphate, etc. The buffer may be used alone or in combination of two or more.
[0063] The administration method of the pharmaceutical composition according to the present embodiment is not particularly limited, and can be administered according to the method generally used as the administration method of pharmaceuticals. The administration route can be oral administration or parenteral administration. In the case of parenteral administration, intravenous administration, intramuscular administration, intradermal administration, subcutaneous administration, transdermal administration, ocular administration, etc. can be cited, but ocular administration is preferably performed as eye drops.
[0064] The pharmaceutical composition according to this embodiment can contain a therapeutically effective amount of the retinal vasodilator according to the first embodiment. "Therapeutically effective amount" refers to the amount of the drug that effectively treats or prevents the target disease. The therapeutically effective amount can vary according to the disease state, age, gender, and weight of the subject of administration. In the pharmaceutical composition according to this embodiment, the therapeutically effective amount of the retinal vasodilator is the amount in which nobiletin can exhibit a retinal vasodilation effect. The pharmaceutical composition according to an embodiment of the present invention may also contain a therapeutically effective amount of nobiletin corresponding to the unit dosage form. For example, the therapeutically effective amount of the vasodilator according to the first embodiment can be, for example, 0.01 to 50% by mass, 0.1 to 40% by mass, 0.1 to 30% by mass, 0.1 to 20% by mass, 0.1 to 10% by mass, 0.1 to 5% by mass, or 0.1 to 3% by mass as the content of nobiletin in the pharmaceutical composition.
[0065] The pharmaceutical composition according to this embodiment can be administered in a therapeutically effective amount of the retinal vasodilator according to the first embodiment. The retinal vasodilator according to this embodiment can be set to 0.01 to 1000 mg per kg of body weight of the subject, as a dose of nobiletin. The above dose can also be 0.15 to 800 mg / kg, 0.5 to 500 mg / kg, 1 to 400 mg / kg or 1 to 300 mg / kg. The dose can be appropriately determined according to the disease state, age, sex and weight of the subject.
[0066] The dosing interval of the pharmaceutical composition according to this embodiment can be appropriately determined according to the patient's symptoms, weight, age, sex, etc., as well as the dosage form and administration method of the pharmaceutical composition, etc. The dosing interval can be set, for example, every few hours, once a day, once every 2 to 3 days, once a week, etc.
[0067] The pharmaceutical composition according to this embodiment contains nobiletin having a strong retinal vasodilator effect as an active ingredient, and thus can effectively improve or prevent retinal vascular disorders. Therefore, diseases associated with retinal vascular disorders can be treated or prevented at an early stage.
[0068] The pharmaceutical composition according to this embodiment contains nobiletin as an active ingredient, which is a type of flavonoid and is a component that is mostly contained in citrus fruits. Therefore, the risk of side effects is small and it is suitable for oral administration and eye drop administration. The effective amount required to improve or prevent retinal circulation disorders can reach the retina without side effects.
[0069] [Other embodiments]
[0070] In one embodiment, the present invention provides a method of treating or preventing a retinal circulation disorder, the method comprising administering nobiliptin to a subject.
[0071] In one embodiment, the present invention provides a method for dilating retinal blood vessels, the method comprising administering nobiliptin to a subject.
[0072] In one embodiment, the present invention provides a method of treating or preventing retinal vascular stenosis or occlusion, the method comprising administering nobiliptin to a subject.
[0073] In one embodiment, the present invention provides a use of nobiletin in the preparation of a pharmaceutical composition for treating or preventing retinal circulatory disorders.
[0074] In one embodiment, the present invention provides a use of nobiliptin in the preparation of a retinal vasodilator.
[0075] In one embodiment, the present invention provides a use of nobiliptin in the preparation of a pharmaceutical composition for treating or preventing retinal vascular stenosis or occlusion.
[0076] In one embodiment, the present invention provides nobiletin for use in treating or preventing retinal circulation disorders.
[0077] In one embodiment, the present invention provides nobiletin for use in dilating retinal blood vessels.
[0078] In one embodiment, the present invention provides a use of nobiletin for treating or preventing retinal vascular stenosis or occlusion.
[0079] In one embodiment, the present invention provides a use of nobiletin for treating or preventing retinal circulation disorders.
[0080] In one embodiment, the present invention provides a use of nobiletin for dilating retinal blood vessels.
[0081] In one embodiment, the present invention provides a use of nobiletin for treating or preventing retinal vascular stenosis or occlusion.
[0082] [Example]
[0083] Hereinafter, the present invention will be described by way of examples, but the present invention is not limited to the following examples.
[0084] [Retinal vasodilation test using porcine retinal arteries]
[0085] Pigs aged 8 to 12 weeks after birth were slaughtered. The eyeballs were immediately removed after slaughter. The retinal arteries were isolated from the removed eyeballs (Nagaoka et al., Invest Ophthalmol Vis Sci. 2007 Feb; 48(2):825-32.). The anterior eye and vitreous were carefully removed using a dissecting microscope. The posterior eye was placed in an ice-cold dissection chamber containing physiological saline solution (PSS: NaCl 145.0 mM, KCl 4.7 mM, CaCl2 2.0 mM, MgSO4 1.17 mM, NaH2PO4 1.2 mM, glucose 5.0 mM, pyruvic acid 2.0 mM, EDTA 0.02 mM, MOPS [3-(N-morpholino)propanesulfonic acid] 3.0 mM) supplemented with 1% albumin. Individual secondary retinal arteries (90-130 μm inner diameter and 0.6-1.0 mm length in situ) were carefully dissected using Dumont microdissecting forceps (Fine Science Tools, Foster City, CA) under observation on a stereomicroscope (model SZX12; Olympus, Melville, NY). After careful removal of remaining neural and connective tissue, the arteries were transferred to a Lusite vascular chamber containing PSS-albumin solution equilibrated with air at room temperature for cannula cannulation. A glass micropipette (30-40 μm outer diameter at the tip) filled with PSS-albumin solution was used to cannulate one end of the artery, and the outside of the artery was securely connected to the pipette with 11-0 ophthalmic sutures (Alcon, Fort Worth, TX). The other end of the vessel was cannulated with a second micropipette and secured with sutures. After cannula intubation, blood vessel and pipette were transferred to the stage of an inverted microscope (model CKX41, Olympus), connected to a video camera (Sony DXC-190, Labtek, Campbell, California), a video micrometer (Cardiovascular Research Institute, Texas A&M System Health Science Center, University City, Texas) and a data acquisition system (PowerLab, Australian Ede Instruments Ltd., Colorado Springs, Colorado), and the internal diameter was continuously measured and recorded during the experiment. The micropipette was connected to an independent pressure reservoir (30mL glass syringe). By adjusting the height of the reservoir, the blood vessel was pressurized to an intracavitary pressure of 55cm H2O (40mmHg).
[0086] The cannulated arteriole was immersed in 36-37°C PSS to generate basal tone. After the blood vessel achieved a stable basal tone (about 30-40 minutes), the vasodilation effect of nobiletin was evaluated. After the control reaction was completed, the blood vessel was washed with PSS to generate basal tone again. Then, nobiletin at various concentrations was applied to the blood vessel for 3-5 minutes until the blood vessel diameter stabilized.
[0087] The vessels were relaxed with EDTA (1 mM)-calcium-free PSS, and the maximum diameter was obtained at an intraluminal pressure of 55 cm H 2 O. The changes in vessel diameter in response to nobiletin were normalized to this maximum vascular dilation and expressed as a percentage relative to the maximum vascular dilation.
[0088] <Example 1>
[0089] According to the above method, the retinal vasodilation test was performed using porcine retinal arteries to evaluate the retinal vasodilation effect of nobiletin.
[0090] Sodium nitroprusside (SNP) was used as a positive control compound.
[0091] In order to evaluate the effect of guanylate synthase on vasodilation by nobiletin, blood vessels were treated with 1H-[1,2,4]oxadiazine-[4,3-a]quinoxaline-1-one (ODQ, 0.1 μM), a guanylate synthase inhibitor, for 30 minutes. The vasodilation effect of nobiletin was evaluated using the blood vessels.
[0092] (result)
[0093] The results are shown in Figure 1 . Nobiletin showed a strong retinal vasodilator effect in a dose-dependent manner. The retinal vasodilator effect of Nobiletin was higher than that of SNP, a standard retinal vasodilator. In addition, by treating the blood vessels with ODQ, a guanylate cyclase inhibitor, the retinal vasodilator effect of Nobiletin was inhibited (Nobiletin+ODQ). This result suggests that the retinal vasodilator effect of Nobiletin is related to the relaxation of vascular smooth muscle via guanylate cyclase.
[0094] <Example 2>-
[0095] According to the above method, retinal vasodilation tests were performed twice using porcine retinal excised arteries (n=5) to evaluate the retinal vasodilation effect of nobiletin.
[0096] The results are shown in Figure 2 In both trials, nobiletin showed the same dose-dependent retinal vasodilation effect.
[0097] <Example 3>
[0098] In order to confirm whether the retinal vasodilator effect of nobiletin is dependent on the vascular endothelium, a retinal vasodilator test was performed using porcine retinal excised arteries in which the vascular endothelium was denuded by perfusing the blood vessels with a surfactant CHAPS solution (n=11).
[0099] The results are shown in Figure 3 The vasodilation effect was suppressed when using porcine retinal explanted arteries from which the vascular endothelium was removed (denudation) compared to when using porcine retinal explanted arteries from which the vascular endothelium was not removed (Nobiretin). This result suggests that the retinal vasodilation effect of Nobiretin is related to the vascular endothelium.
[0100] <Example 4>
[0101] In the same manner as in Example 1, porcine retinal excised arteries were treated with ODQ, and the effect of guanylate cyclase on the retinal vasodilation effect of nobiletin was evaluated (n=7).
[0102] The results are shown in Figure 4 As in Example 1, the addition of ODQ, a guanylate cyclase inhibitor, inhibited the retinal vasodilation effect of nobiletin (Nobiletin+ODQ). This result strongly suggests that the retinal vasodilation effect of nobiletin is related to the relaxation of vascular smooth muscle via guanylate cyclase.
[0103] (Comparison of Nobiletin with known drugs)
[0104] Table 1 shows the comparison of the maximum vasodilation rate of retinal blood vessels with known drugs. The concentration of the solvent used to dissolve the test substance was used within the range that did not affect the vasodilation effect. When compared with known drugs excluding the influence of the solvent, it was shown that nobiletin showed the strongest vasodilation effect.
[0105] [Table 1]
[0106]
[0107] [Industrial Applicability]
[0108] According to the present invention, a new retinal vasodilator and a pharmaceutical composition comprising the retinal vasodilator are provided.
[0109] The preferred embodiments of the present invention are described above, but the present invention is not limited to these embodiments. Additions, omissions, substitutions and other changes to the structure can be made without departing from the scope of the present invention. The present invention is not limited by the foregoing description, but only by the scope of the appended claims.
Claims
1. A retinal vasodilator comprising nobiliptin.
2. A pharmaceutical composition for treating or preventing retinal circulatory disorders, comprising the retinal vasodilator according to claim 1 and a pharmaceutically acceptable carrier.
